Arcus Biosciences IPO

3/15/2018

IPO

$120,000,000

The company will use approximately $55.0 million to fund the clinical development of AB928 (our dual A2aR/A2bR antagonist) and AB122 (our anti-PD-1 antibody), including potential milestone payments to WuXi Biologics; and the remaining proceeds to fund the development of other product candidates in our pipeline, including AB680 (our CD73 inhibitor) and AB154 (our anti-TIGIT antibody), our drug discovery and optimization programs, and other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

3928 Point Eden Way
Hayward, CA 94545
USA

Undisclosed

Arcus Biosciences (NYSE: RCUS) The field of immuno-oncology (or cancer immunotherapy) has exploded in the past decade. Cancer immunotherapies generally work by interfering with the inhibitory signals produced by tumors against certain elements of the immune system. Arcus is initially developing drug therapies for small molecules along the ATP-adenosine pathway.